Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Piotr, Chmielewski" wg kryterium: Autor


Wyświetlanie 1-3 z 3
Tytuł:
Effect of a bicarbonate-buffered peritoneal dialysis solution on clinical and laboratory indices of dialysis adequacy
Autorzy:
Chmielewski, Michał
Bielińska-Ogrodnik, Dorota
Jagodziński, Piotr
Lichodziejewska-Niemierko, Monika
Powiązania:
https://bibliotekanauki.pl/articles/895747.pdf
Data publikacji:
2020-05-29
Wydawca:
Gdański Uniwersytet Medyczny
Tematy:
peritoneal dialysis
acid-base balance
end-stage renal failure
bicarbonate-based solutions
Opis:
Background: Biocompatible fluids were introduced to improve dialysis and patient outcome in end-stage renal disease. However, being buffered with lactate, they may insufficiently correct metabolic acidosis, and lead to changes in peritoneum structure. Bicarbonate buffered fluids might mitigate these complications. The aim of the study was to evaluate the influence of a bicarbonate dialysis fluid on clinical and laboratory indices of dialysis adequacy. Material and methods: 20 prevalent peritoneal dialysis (PD) patients created two groups. One group continued on lactate fluid, the other changed to bicarbonate solution. Clinical and laboratory indices of dialysis adequacy were evaluated at baseline, and at six weeks intervals for 24 weeks. Results: In bicarbonate group, pH was 7.36±0.03, HCO3 22.1±1.8 mmol/l at baseline and 7.36±0.04 and 21.2± 2.3 mmol/l at 24 weeks, while in controls pH equaled 7.35±0.12, HCO3 22.2±1.4 mmol/l, at baseline, and 7.40±0.03, and 22.3±1.8 mmol/l, at 24 weeks, with no significant differences. Dialysis adequacy (urea Kt/V), urine output and dialysis ultrafiltration did not differ between the groups, either at baseline or at study termination. Conclusions: Bicarbonate PD solution appears to be similar to standard fluid in the impact on hydration status and on acid/base balance. Longitudinal studies are needed to assess long-term advantages of these biocompatible solutions.
Źródło:
European Journal of Translational and Clinical Medicine; 2020, 3, 1; 11-15
2657-3148
2657-3156
Pojawia się w:
European Journal of Translational and Clinical Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The use of over-the-counter analgesics in patients with chronic kidney disease
Autorzy:
Jakimowicz-Tylicka, Marzena
Chmielewski, Michał
Kuźmiuk-Glembin, Izabella
Skonieczny, Piotr
Dijakiewicz, Grażyna
Zdrojewska, Grażyna
Rutkowski, Bolesław
Tylicki, Leszek
Dębska-Ślizień, Alicja
Powiązania:
https://bibliotekanauki.pl/articles/895741.pdf
Data publikacji:
2019-02-05
Wydawca:
Gdański Uniwersytet Medyczny
Tematy:
chronic kidney disease
analgesics
over-the-counter
Opis:
Background: Analgesics can be sold following medical prescription, but also as over-the-counter (OTC) medications. In patients with chronic kidney disease (CKD), their use could potentially be associated with increased risk of side-effects, due to impaired renal elimination. The aim was to evaluate the epidemiology and indications for the use of OTC analgesics, and the knowledge of their side-effects in patients with CKD. Material and methods: A cross-sectional, controlled survey on the use of OTC analgesic drugs was conducted among 180 CKD patients (stage 1-5, dialysis, kidney transplant), compared to 60 controls. Results: The proportion of patients using OTC analgesics on a regular basis was higher in the CKD group, compared to controls (18.9% vs. 10.0%, p<0.02). The major indications included musculoskeletal issues, followed by headaches and other. Subgroup analysis revealed that analgesic use was lowest among transplanted patients, in comparison to CKD stage 1-5, and dialysis subjects (10%, 20%, 26%, respectively, p=0.06). Less than half of CKD patients and controls declared any knowledge on potential side-effects of analgesic drugs (45.6% vs. 40.0%, NS). Conclusions: The use of OTC analgesics among patients with CKD is higher than in subjects without CKD, with the exception of transplanted patients. The knowledge on the potential side-effect of analgesics is limited.
Źródło:
European Journal of Translational and Clinical Medicine; 2018, 1, 2; 11-16
2657-3148
2657-3156
Pojawia się w:
European Journal of Translational and Clinical Medicine
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Dietary supplement use among patients with chronic kidney disease
Autorzy:
Jakimowicz-Tylicka, Marzena
Chmielewski, Michał
Kuźmiuk-Glembin, Izabella
Skonieczny, Piotr
Dijakiewicz, Grażyna
Zdrojewska, Grażyna
Rutkowski, Bolesław
Tylicki, Leszek
Dębska Ślizień, Alicja
Powiązania:
https://bibliotekanauki.pl/articles/1038410.pdf
Data publikacji:
2018
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
dietary supplements
vitamins
minerals
chronic kidney disease
dialysis
toxicity
Opis:
Background. Dietary supplements (DS) are available over the counter, but patients with impaired renal function are specifically at risk for toxicity when consuming certain DS. The aim of this study was to evaluate the prevalence and characteristics of DS use in patients with chronic kidney disease (CKD). Material and methods. A cross-sectional, controlled DS use survey (22 questions) was conducted among 180 CKD patients (stage 1-5, dialysis, kidney transplant), with 60 patients without CKD serving as controls. Results. DS use did not differ significantly between subjects with and without CKD, unless the CKD patients were on dialysis. In the CKD group, 20% admitted to use DS regularly and 22% did not take the mat all. In the controls, DS consumption was 17% and 13%, respectively (NS). The DS use was higher among women ascompared to men (89% vs. 70%; p < 0.005), and people living in cities versus those living in the country side (81% vs. 63%; p < 0.05). DS most commonly used were: vitamins, minerals, and herbs. Major indications for DS use included: musculoskeletal issues, general health improvement and prevention of urinary tract infections. Subgroup analyses revealed that dialysis patients were characterized by a significantly higher DS use in comparison to CKD stage 1-5 subjects and renal transplant recipients. The decision to introduce DS was made by the physician in 54% of cases; by a pharmacist in 9% of cases, and by the patients themselves in 37%. Only 21% of patients with CKD, and 27% of subjects without CKD, declared knowledge of any possible side-effects associated with DS (NS). Conclusions. The use of DS among patients with CKD is similar to patients without CKD, with the exception of those on dialysis. Vitamins and minerals were the most commonly reported DS consumed. The knowledge on potential side-effectof DS was limited to approximately one-fourth of those surveyed.
Źródło:
Acta Biochimica Polonica; 2018, 65, 2; 319-324
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-3 z 3

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies